About Telesis Bio
Telesis Bio is a company based in San Diego (United States) founded in 2013. Telesis Bio has raised $25 million across 2 funding rounds from investors including Oxford Finance, Broadoak Capital Partners and Novalis LifeSciences. Telesis Bio has completed 1 acquisition, including Eton Bioscience. Telesis Bio offers products and services including BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA. Telesis Bio operates in a competitive market with competitors including Amyris, Syngenta, AskBio, Quanterix and Ginkgo Bioworks, among others.
- Headquarter San Diego, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Telesis Bio, Inc.
-
Annual Revenue
$27.51 M (USD)0.27as on Dec 31, 2023
-
Net Profit
-$47.72 M (USD)1.54as on Dec 31, 2023
-
EBITDA
-$31.05 M (USD)28.81as on Dec 31, 2023
-
Total Equity Funding
$25 M (USD)
in 2 rounds
-
Latest Funding Round
$28 M (USD), Post-IPO
May 31, 2023
-
Investors
Oxford Finance
& 4 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Telesis Bio
Telesis Bio is a publicly listed company on the OTC with ticker symbol TBIO in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Telesis Bio
Telesis Bio offers a comprehensive portfolio of products and services, including BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA.
Fully automated tool for DNA and mRNA synthesis in research labs
Compact system for gene assembly and amplification processes
Scalable device for large-scale DNA workflows
Technique for efficient DNA fragment assembly in experiments
People of Telesis Bio
Unlock access to complete
Funding Insights of Telesis Bio
Telesis Bio has successfully raised a total of $25M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Telesis Bio
Telesis Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Oxford Finance, Broadoak Capital Partners and Novalis LifeSciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and advisory services are provided for life sciences.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked |
Investor details for Telesis Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Telesis Bio
Telesis Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eton Bioscience.
Investment portfolio details for Telesis Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
DNA sequencing products and genomic services are developed and provided.
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for Telesis Bio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Telesis Bio
Detailed financials for Telesis Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Telesis Bio Comparisons
Peer comparison for Telesis Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Telesis Bio
Telesis Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, AskBio, Quanterix and Ginkgo Bioworks, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Assay kits for ultra-sensitive biomarker detection are developed.
|
|
| Locked | Locked | Locked |
Gene editing-based cultured ingredients are provided for agriculture.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
Detailed competitors of Telesis Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Telesis Bio
Complete news archive for Telesis Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Telesis Bio
Telesis Bio was founded in 2013 and raised its 1st funding round 6 years after it was founded.
Telesis Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Todd R Nelson is the current CEO of Telesis Bio.
Telesis Bio is a funded company, having raised a total of $25M across 2 funding rounds to date.
Annual revenue of Telesis Bio is $27.51M as on Dec 31, 2023.
Online platform offering life sciences reagents and kits. The companys products include the BioXp system, BioXp kits, and Benchtop reagents. Also, it develops vaccines, therapeutics, and diagnostics to combat the COVID-19 pandemic.
Telesis Bio offers BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA.
Yes, Telesis Bio is publicly traded on OTC under the ticker symbol TBIO.
Telesis Bio has made 1 acquisition, including Eton Bioscience.
Telesis Bio has 5 investors. Key investors include Oxford Finance, Broadoak Capital Partners, Novalis LifeSciences, Northpond Ventures, and M 185 Corporation.
The ticker symbol of Telesis Bio is TBIO on OTC.